Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
18477783
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Boston University, School of Medicine, Renal Section, EBRC 504, 650 Albany St, Boston, Massachusetts 02118, USA. ldember@bu.edu
DOI:
https://doi.org/10.1001/jama.299.18.2164
Authors:
Lightfoot T,
Greenberg A,
Berkoben M,
Kovalik E,
Lawson J,
Middleton J,
Schwab S,
Schumm D,
Adams S,
Gitter K,
Cantaffa T,
Quarles A,
Himmelfarb J,
Whiting J,
Kane J,
Freedman S,
Violette R,
Cyr-Alves H,
Garrison K,
Allon M,
Robbin M,
Lockhart M,
Casey B,
Newsome J,
Dixon B,
Franzwa B,
Hunsicker L,
Hoballah J,
Katz D,
Sharp W,
Kresowik T,
Wu Y,
Rayhill S,
Pflederer T,
DuPage K,
Welch K,
Darras F,
Banqero B,
Ketel B,
Arrow AW,
Grant C,
Deep J,
Pyszka L,
Vazquez M,
Davidson I,
Toto R,
Littmon L,
Ying C,
Berkowitz A,
Quinones H,
Saxena R,
Clagett P,
Valentine J,
Dolmatch B,
Thompson J,
Fenves A,
Pearl G,
Ikizler T,
Egbert P,
Rocco M,
Daeihagh P,
Tuttle A,
Mauck V,
Hoosier T,
McBride D,
Delmez J,
Windus D,
Coyne D,
Rothstein M,
Shenoy S,
Creaghan R,
Lluka B,
Kusek J,
Meyers C,
Feldman H,
Beck G,
Gassman J,
Greene T,
Hu B,
Bi S,
Liu A,
Radeva M,
Tuason L,
Weiss B,
Levin N,
Besarab A,
Chertow G,
Diener-West M,
Louis T,
McClellan W,
Stehman-Breen C,
Rocco MV,
Davidson IJ,
Kaufman JS,
Meyers CM,
Kusek JW,
Feldman HI,
Dialysis Access Consortium Study Group,
Dember L,
Kaufman J,
Hawley M,
Lauer A,
LeSage P,
Nathan R,
Ryan M,
Holmberg E,
Braden G,
Dember LM,
Beck GJ,
Allon M,
Delmez JA,
Dixon BS,
Greenberg A,
Himmelfarb J,
Vazquez MA,
Gassman JJ,
Greene T,
Radeva MK,
Braden GL,
Ikizler TA
Studies:
Dialysis Access Consortium
,
Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis
The arteriovenous fistula is the preferred type of vascular access for hemodialysis because of lower thrombosis and infection rates and lower health care expenditures compared with synthetic grafts or central venous catheters. Early failure of fistulas due to thrombosis or inadequate maturation is a barrier to increasing the prevalence of fistulas among patients treated with hemodialysis. Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas.
